pimavanserin-is-a-selective-serotonin-receptor-modulating-agent-with-inverse-agonist-antagonist-activity-at-the-5ht2a-receptor-and-to-a-lesser
Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration
Gemcitabine is a nucleoside analog effective against several solid tumors.
3D Printed Buccal Films for Prolonged-Release of Propranolol Hydrochloride: Development, Characterization and Bioavailability Prediction
Gelatin-polyvinylpyrrolidone (PVP) and gelatin-poly(vinyl alcohol) (PVA) mucoadhesive buccal films loaded with propranolol hydrochloride (PRH) were prepared by semi-solid extrusion 3D printing.
Current Practices, Gap Analysis and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective
The International Consortium for Innovation and Quality (IQ) Physiologically Based Pharmacokinetic modeling (PBPK) Induction Working Group (IWG) conducted a survey across participating companies around general strategies for PBPK modeling of...
Internship+ Flyer
Opportunities to apply model informed drug development (MIDD) skills and methods with Simulations Plus.
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
Complementing the existing distributorship with ADMET Predictor® and GastroPlus® software
Stimuli to the Revision Process: The Case for Apex Vessels Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts
Apex vessels (previously known as PEAK vessels) are an important element of the dissoluton scientst's toolbox and are frequently used in pharmaceutcal drug product development setngs
Yo-Yo Dieting Predicted to Contribute to Fibrosis Score Reductions in Untreated (Placebo) Cohorts
In November 2021, at the AASLD annual meeting, we presented simulation results demonstrating that yo-yo dieting, particularly...
Validation of non-compartmental analysis (NCA) and bioequivalence results of PKanalix with respect to Phoenix WinNonLin
Non-compartmental analysis (NCA) is used at all stages of drug development and is a key method to understand the pharmacokinetic properties of a compound.
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope
Expanding access to high-quality medication for people in need
Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia
Sodium oxybate (SXB) is a standard of care for cataplexy, excessive daytime sleepiness, and disrupted nighttime sleep in narcolepsy.
Meet the Scientist, Kelly Fellows Maxwell, PhD – Assistant Director, Pharmacometrics
I graduated with my PhD in Pharmaceutical Sciences from the University of Buffalo in June 2018 and began working at Cognigen right after that.
PBPK Modeling and Simulation and Therapeutic Drug Monitoring: Possible Ways for Antibiotic Dose Adjustment
Pharmacokinetics (PK) is a branch of pharmacology present and of vital importance for the research and development (R&D) of new drugs, post-market monitoring, and continued optimizations in clinical contexts.
Ulcerogenic Activity in Pyrazolopyrimidine Derivatives in Lab and It’s In Silico Toxicity: An Update on Novel Research
Toxicity is a measure of any unfavourable or negative impact of substances.
Simulations Plus Names Sharlene Evans to Board of Directors
Experienced Human Resource, Development and Organizational Leader Bolsters Board
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference
Yo-Yo dieting without additional treatment can explain high placebo response rates in NASH clinical trials
Application of PBPK modeling & simulation to support dose selection in special populations – Bilastine as a case example
Dose recommendations are usually established using data driven approaches, i.e., population modeling & simulation...
November 2021 GastroPlus Newsletter
Only 52 days left in 2021!
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
New RENAsym platform helps drug developers avoid kidney injury side effects
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym...